147 related articles for article (PubMed ID: 8679054)
1. Synthesis of a series of cytotoxic 2-acyl-1,2-dihydroellipticines which inhibit topoisomerase II.
Devraj R; Jurayj J; Fernandez JA; Barrett JF; Cushman M
Anticancer Drug Des; 1996 Jun; 11(4):311-24. PubMed ID: 8679054
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity.
Kim JS; Rhee HK; Park HJ; Lee IK; Lee SK; Suh ME; Lee HJ; Ryu CK; Choo HY
Bioorg Med Chem; 2007 Jan; 15(1):451-7. PubMed ID: 17035025
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
[TBL] [Abstract][Full Text] [Related]
4. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.
Kim MY; Duan W; Gleason-Guzman M; Hurley LH
J Med Chem; 2003 Feb; 46(4):571-83. PubMed ID: 12570378
[TBL] [Abstract][Full Text] [Related]
6. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
Zeng Q; Kwok Y; Kerwin SM; Mangold G; Hurley LH
J Med Chem; 1998 Oct; 41(22):4273-8. PubMed ID: 9784102
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors.
Kamal A; Atchison K; Daneshtalab M; Micetich RG
Anticancer Drug Des; 1995 Oct; 10(7):545-54. PubMed ID: 7495478
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel isoellipticine derivatives and salts.
Miller CM; O'Sullivan EC; Devine KJ; McCarthy FO
Org Biomol Chem; 2012 Oct; 10(39):7912-21. PubMed ID: 22940706
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
Fossé P; René B; Charra M; Paoletti C; Saucier JM
Mol Pharmacol; 1992 Oct; 42(4):590-5. PubMed ID: 1331751
[TBL] [Abstract][Full Text] [Related]
10. Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogues as novel topoisomerase II inhibitors.
Guan J; Zhu XK; Tachibana Y; Bastow KF; Brossi A; Hamel E; Lee KH
J Med Chem; 1998 May; 41(11):1956-61. PubMed ID: 9599244
[TBL] [Abstract][Full Text] [Related]
11. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
12. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of bengacarboline derivatives.
Pouilhès A; Kouklovsky C; Langlois Y; Baltaze JP; Vispé S; Annereau JP; Barret JM; Kruczynski A; Bailly C
Bioorg Med Chem Lett; 2008 Feb; 18(3):1212-6. PubMed ID: 18083028
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates.
Devraj R; Barrett JF; Fernandez JA; Katzenellenbogen JA; Cushman M
J Med Chem; 1996 Aug; 39(17):3367-74. PubMed ID: 8765520
[TBL] [Abstract][Full Text] [Related]
15. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.
Zhao R; al-Said NH; Sternbach DL; Lown JW
J Med Chem; 1997 Jan; 40(2):216-25. PubMed ID: 9003520
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition by ellipticine derivatives of the reactions catalysed by the topoisomerases: preferential inhibition of topoisomerase II].
Douc-Rasy S; Multon E; Kayser A; Riou G
C R Seances Acad Sci III; 1983; 296(19):899-904. PubMed ID: 6311366
[TBL] [Abstract][Full Text] [Related]
17. 2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Basnet A; Thapa P; Karki R; Na Y; Jahng Y; Jeong BS; Jeong TC; Lee CS; Lee ES
Bioorg Med Chem; 2007 Jul; 15(13):4351-9. PubMed ID: 17493824
[TBL] [Abstract][Full Text] [Related]
18. DNA binding ellipticine analogues: synthesis, biological evaluation, and structure-activity relationships.
Ferlin MG; Marzano C; Gandin V; Dall'Acqua S; Dalla Via L
ChemMedChem; 2009 Mar; 4(3):363-77. PubMed ID: 19197924
[TBL] [Abstract][Full Text] [Related]
19. [In vitro stimulation by ellipticine derivatives of DNA cleavage induced by DNA topoisomerase II: a structure-activity relationship].
Fossé P; Charra M; Paoletti C; Saucier JM; René B
Bull Cancer; 1994 Mar; 81(3):194-202. PubMed ID: 7894127
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1.
Malonne H; Farinelle S; Decaestecker C; Gordower L; Fontaine J; Chaminade F; Saucier JM; Atassi G; Kiss R
Clin Cancer Res; 2000 Sep; 6(9):3774-82. PubMed ID: 10999772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
